Amicus Therapeutics: Too Cheap At Under $10 A Share

The company also markets Pombiliti + Opfolda, which was recently approved (October 2023) to treat adults with late-onset Pompe disease (LOPD). Management believes these two products have north of $1.5 billion peak sales potential combined. The stock trades for around $9.50 a share and has a market cap of just north of $2.8 billion. avdeev007 Today, we put rare disease concern Amicus Therapeutics (NASDAQ:FOLD) under the spotlight. The shares have recently slid under the $10 a share level, which seems too che ...